JonesTrading analyst Justin Walsh has reiterated their bullish stance on PRAX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Praxis Precision Medicines’ epilepsy portfolio. The recent clinical update at the 2025 American Epilepsy Society Annual Meeting highlighted significant advancements, particularly with the EMBOLD trial of relutrigine, which was stopped early due to its efficacy. The trial results showed a notable placebo-adjusted seizure reduction and an increase in motor seizure-free days, with positive feedback from clinicians and caregivers regarding patient improvement.
Additionally, the RADIANT trial results for vormatrigine were promising, indicating its potential as a best-in-disease antiseizure medication. Vormatrigine demonstrated a significant reduction in seizures, with a substantial portion of patients achieving seizure freedom without the need for titration. The drug also showed a favorable interaction profile, making it suitable for multi-drug regimens. With these encouraging outcomes and upcoming pivotal study data, Walsh sees strong potential for Praxis Precision Medicines’ assets to benefit a wide range of patients, justifying the Buy rating.
In another report released today, Guggenheim also reiterated a Buy rating on the stock with a $760.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.